A 62-year-old man from Delhi presents with a 3-year history of progressive tremor at rest in his right hand, rigidity, and bradykinesia. His wife reports he has become emotionally withdrawn and shows reduced facial expression. Neuroimaging is normal. On examination, he has a classic 'pill-rolling' tremor and cogwheel rigidity. Based on the presumed pathophysiology of basal ganglia dysfunction, what is the most appropriate immediate pharmacological intervention?

Explanation

## Clinical Diagnosis **Key Point:** The clinical presentation—resting tremor, rigidity, bradykinesia, and postural instability—is pathognomonic for Parkinson disease (PD), caused by degeneration of dopaminergic neurons in the substantia nigra pars compacta. ## Basal Ganglia Circuitry in Parkinson Disease ```mermaid flowchart TD A[Normal: Substantia nigra dopaminergic neurons intact]:::outcome --> B[Dopamine inhibits indirect pathway<br/>Facilitates direct pathway]:::outcome B --> C[Balance: Direct > Indirect pathway]:::outcome C --> D[Normal motor output]:::outcome E[Parkinson Disease: Loss of dopaminergic neurons]:::urgent --> F[Reduced dopamine]:::urgent F --> G[Indirect pathway overactive<br/>Direct pathway underactive]:::urgent G --> H[Excessive inhibition of thalamus]:::urgent H --> I[Bradykinesia, rigidity, tremor]:::urgent ``` **High-Yield:** In PD, the loss of dopamine causes: - **Direct pathway** (facilitatory) → hypoactive - **Indirect pathway** (inhibitory) → hyperactive - Net result: excessive GABAergic inhibition of the thalamus → motor slowing and rigidity ## Why Levodopa Is First-Line | Feature | Levodopa + Carbidopa | Benztropine | Amantadine | Haloperidol | |---------|----------------------|-------------|-----------|-------------| | **Mechanism** | Dopamine precursor (crosses BBB); carbidopa blocks peripheral decarboxylase | Anticholinergic (blocks cholinergic overactivity) | NMDA antagonist; weak dopamine agonist | D2 antagonist (worsens PD) | | **Efficacy in PD** | Gold standard; addresses core deficit | Mild tremor relief only | Modest benefit; mainly tremor | Contraindicated | | **Indications** | All motor symptoms (tremor, rigidity, bradykinesia) | Tremor-dominant, mild cases | Tremor, rigidity (adjunct) | **Never in PD** | | **Onset** | 30–60 min | Slower | Slower | N/A | **Clinical Pearl:** Levodopa (not dopamine itself) crosses the blood–brain barrier via the large neutral amino acid transporter. Carbidopa is a peripheral decarboxylase inhibitor that prevents premature conversion of levodopa to dopamine in the periphery, maximizing brain delivery and reducing GI side effects. **Key Point:** Benztropine and amantadine are adjunctive agents for tremor or mild disease; they do NOT address the fundamental dopamine deficit and are inadequate as monotherapy in symptomatic PD. **Warning:** Haloperidol is a D2 antagonist and will **worsen** Parkinson symptoms by further blocking dopamine signaling—a common trap in exams. ## Recommended Next Step Initiate **levodopa 100 mg with carbidopa 25 mg** (or 50/200 formulation), titrated gradually to minimize side effects (nausea, dyskinesias). This directly replaces the lost dopamine and restores the balance of direct and indirect pathway activity.